- Lifecore Biomedical selected by Lindy Biosciences to provide contract manufacturing services for innovative drug delivery technology.
- The multi-year agreement could generate over $5 million for Lifecore.
Lifecore Biomedical, Inc. has been selected by Lindy Biosciences to provide contract development and manufacturing services (CDMO) for the company’s microglassification technology. The partnership aims to streamline the formulation process and scale the technology for commercial manufacturing, with a multi-year agreement expected to bring Lifecore more than $5 million in revenue.
The collaboration follows a competitive selection process in which Lindy Biosciences reviewed several CDMOs before choosing Lifecore Biomedical. Lindy’s proprietary microglassification platform, which has attracted attention from leading pharmaceutical companies, is designed to enable the delivery of high concentrations of biologics through pre-filled syringes or autoinjectors, potentially shifting treatments from clinical settings to self-administration at home.
“When deciding to select Lifecore for this important work, we were particularly drawn to the company’s creativity and willingness to collaborate,” said Dr. Deborah Bitterfield, CEO of Lindy Biosciences. She highlighted Lifecore’s role in optimizing the process and scaling it for commercial use.
Lifecore’s expertise in the development and production of sterile injectable pharmaceutical products positions it as a strong partner for the project. Darren Hieber, Lifecore’s senior vice president of corporate development and partnerships, noted that the collaboration will further enhance Lifecore’s role as a preferred CDMO for innovative technologies like microglassification.
Overview of outsourcing trends 
